Starpharma deal with Dow out of the bag
Thursday, 20 January, 2005
Starpharma (ASX:SPL) was forced into a trading halt this morning after a report in Melbourne broadsheet The Age revealed that Starpharma's US subsidiary Dendritic Nanotechnologies (DNT) was about to consummate an intellectual property deal with US giant Dow Chemical company.
At time of writing, Starpharma had not yet provided the market with clarification on the deal. It reportedly involves the transfer of approximately 200 of Dow's nanotechnology patents, including patents in the dendrimer field in which Starpharma specialises. Dow was to receive an equity stake in DNT as consideration.
In November, Starpharma reported positive preliminary results from the Phase I clinical trial on its dendrimer-based vaginal microbicide Vivagel.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
